A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

To join this study, you must be an adult aged 18 or older with non-small cell lung cancer that is in stage II, IIIA, or IIIB. Importantly, your doctors must believe that your cancer can be removed through surgery. You'll need to have clear signs of your cancer that can be measured, and the study will require a sample of your tumour tissue. Your general health and fitness, often measured by something called an ECOG score, should be good (either 0 or 1), and your organs and blood should be working well.

There are also some reasons why you wouldn't be able to join. For example, if you've already received other cancer treatments like chemotherapy or radiotherapy for this particular lung cancer, you wouldn't be eligible. If your cancer has certain genetic changes (called EGFR or ALK mutations) or if you have severe numbness or tingling in your hands and feet (peripheral neuropathy), you also can't take part. You also shouldn't have another active cancer or certain heart conditions.

For some parts of the study, there are additional specific reasons why you might not be able to join. These include certain high levels of calcium in your blood or specific brain conditions that could be risky with the study treatment. The research team will go through all these details with you to make sure the study is a safe and suitable option.

Taking part in this study would involve regular visits to the hospital or clinic. During these visits, you would receive the study medication (either the two-drug or three-drug combination) and have various tests and assessments. These might include blood tests to check your general health and how the study drugs are affecting you, as well as scans to see how your cancer is responding. You would also have physical examinations and answer questions about how you are feeling and any side effects you might be experiencing.

After you've completed the initial treatment phase and likely undergone surgery, there will be a follow-up period. This involves continued monitoring, which could include further check-ups, scans, and blood tests to track your health and look for any long-term effects of the treatment. The total duration of your participation in the study, including treatment and follow-up, will be explained in detail by the study team, but it typically lasts for many months or even a few years.